Eastwood Bio-Medical Canada Inc (TSE:EBM)

:EBM

EBM

Eastwood Bio-Medical Canada

RESEARCH TOOLSreports

Eastwood Bio-Medical Canada (EBM) Price & Analysis

5 Followers

EBM Stock Chart & Stats

C$0.80

>-C$0.01(-1.00%)

At close: Jan 08 4:00 PM EST

C$0.80

>-C$0.01(-1.00%)

Day’s Range― - ―

52-Week RangeC$0.30 - C$1.10

Previous CloseN/A

Volume2.20K

Average Volume (3M)3.49K

Market Cap

C$62.00M

Enterprise ValueC$66.56M

Total Cash (Recent Filing)C$17.70K

Total Debt (Recent Filing)C$78.01K

Price to Earnings (P/E)―

Beta-0.06

Next Earnings

Jul 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding68,885,970

10 Day Avg. Volume3,055

30 Day Avg. Volume3,488

Financial Highlights & Ratios

PEG Ratio5.31

Price to Book (P/B)-29.59

Price to Sales (P/S)61.66

P/FCF Ratio2.50K

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue Rebound & High Gross MarginA durable ~32% revenue rebound with sustained ~65% gross margins improves unit economics and shows demand-plus-pricing power. If management controls operating spend, this combination materially increases the odds of translating top-line gains into lasting profitability over the next several quarters.

Positive Operating Cash Flow In 2025Returning to positive operating and free cash flow, even at a small scale, signals improving cash conversion and operational discipline. Sustained positive OCF reduces reliance on external capital, improving resilience and funding runway over a multi-quarter horizon if the trend continues.

Branded Product & Multi-channel DistributionA flagship brand (Eleotin), research-backed formulations and multi-channel distribution create structural advantages: stronger consumer trust, diversified revenue streams and scalable go-to-market options. This supports durable demand and lowers single-channel concentration risk over months.

Bears Say

Negative, Deteriorating Shareholders' EquityPersistently negative and worsening equity constrains financial flexibility, hampers access to capital markets and raises recapitalization or going-concern risk. This structural balance-sheet weakness can force dilutive financing or restructuring, limiting strategic options over the medium term.

Deep, Persistent Operating LossesLarge negative net margins and recurring negative EBIT/EBITDA indicate the core cost base is not yet scalable to profitability. Without sustained margin improvement, the company will remain dependent on external funding, increasing execution risk and undermining long-term viability.

Small Cash Generation Versus Scale Of LossesAlthough OCF turned slightly positive, absolute cash generation is tiny versus historical losses and FCF fell year-over-year. This limited buffer leaves the company exposed to shocks and means any sustained investment or cost overruns will likely require external capital within months.

EBM FAQ

What was Eastwood Bio-Medical Canada Inc’s price range in the past 12 months?

Eastwood Bio-Medical Canada Inc lowest stock price was C$0.29 and its highest was C$1.10 in the past 12 months.

What is Eastwood Bio-Medical Canada Inc’s market cap?

Eastwood Bio-Medical Canada Inc’s market cap is C$62.00M.

When is Eastwood Bio-Medical Canada Inc’s upcoming earnings report date?

Eastwood Bio-Medical Canada Inc’s upcoming earnings report date is Jul 06, 2026 which is in 94 days.

How were Eastwood Bio-Medical Canada Inc’s earnings last quarter?

Currently, no data Available

Is Eastwood Bio-Medical Canada Inc overvalued?

According to Wall Street analysts Eastwood Bio-Medical Canada Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Eastwood Bio-Medical Canada Inc pay dividends?

Eastwood Bio-Medical Canada Inc does not currently pay dividends.

What is Eastwood Bio-Medical Canada Inc’s EPS estimate?

Eastwood Bio-Medical Canada Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Eastwood Bio-Medical Canada Inc have?

Eastwood Bio-Medical Canada Inc has 68,885,970 shares outstanding.

What happened to Eastwood Bio-Medical Canada Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Eastwood Bio-Medical Canada Inc?

Currently, no hedge funds are holding shares in TSE:EBM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Eastwood Bio-Medical Canada Inc

Eastwood Bio-Medical Canada Inc. markets and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia. It distributes Eleotin that provide natural remedies for metabolic disorders, such as blood glucose disorders, hypertension, and obesity. The company's licensed products include Eleotin A 700 for the treatment for spleen deficiency, lack of appetite, and fatigue; Eleotin AL88 for laxative; Eleotin Cal20 for bone and teeth maintenance; Eleotin V3D for development and maintenance of bones, teeth, and good health; Eleotin G2000 for cardiovascular health; Eleotin H55 for sedative and tension relief; and Eleotin Zn330 for tissue formation and metabolism. Its products also include Eleotin Bentley to promote healthy glucose levels; and Eleotin LBM for hypertension relief. The company was incorporated in 2010 and is based in Richmond, Canada.